Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares

Immuneering Corporation (NASDAQ:IMRX) insider Harold Eugene Brakewood purchased 5,250 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was purchased at an average cost of $4.76 per share, for a total transaction of $24,990.00. Following the transaction, the insider owned 11,050 shares of the company’s stock, valued at approximately $52,598. This trade represents a 90.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Immuneering Trading Up 1.5%

NASDAQ IMRX opened at $4.85 on Thursday. Immuneering Corporation has a 1 year low of $1.10 and a 1 year high of $10.08. The company has a fifty day simple moving average of $6.25 and a 200 day simple moving average of $5.83. The company has a market cap of $313.16 million, a P/E ratio of -2.72 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last released its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Equities research analysts forecast that Immuneering Corporation will post -1.86 EPS for the current fiscal year.

Analysts Set New Price Targets

IMRX has been the subject of several recent analyst reports. Oppenheimer increased their target price on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Mizuho set a $12.00 price objective on Immuneering in a research report on Wednesday, October 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immuneering has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Institutional Trading of Immuneering

Several institutional investors and hedge funds have recently modified their holdings of IMRX. Sanofi bought a new position in Immuneering during the third quarter valued at $18,960,000. Vanguard Group Inc. lifted its stake in shares of Immuneering by 128.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Immuneering during the 3rd quarter valued at about $6,602,000. Blue Owl Capital Holdings LP purchased a new position in Immuneering in the 3rd quarter worth approximately $3,850,000. Finally, Monashee Investment Management LLC purchased a new stake in Immuneering during the 3rd quarter valued at $2,100,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.